China Botanic Pharmaceutical (CBPI) financial statements (2022 and earlier)
Company profile
| Business Address |
80 BROAD STREET NEW YORK, NY 10004 |
| State of Incorp. | |
| Fiscal Year End | October 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 1/31/2022 Q1 | 10/31/2021 Q4 | 7/31/2021 Q3 | 4/30/2021 Q2 | 1/31/2021 Q1 | 10/31/2020 Q4 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Noncurrent Assets | ||||||||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Due to related parties | 72 | 31 | 22 | 6 | ||||
| Total current liabilities: | 72 | 31 | 22 | 6 | ||||
| Noncurrent Liabilities | ||||||||
| Total liabilities: | 72 | 31 | 22 | 6 | ||||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | (72) | (31) | (22) | (6) | ||||
| Preferred stock | 1 | 1 | 1 | |||||
| Common stock | 37 | 37 | 37 | 37 | 37 | |||
| Additional paid in capital | 11,998 | 11,998 | 11,705 | 11,705 | ||||
| Accumulated deficit | (12,108) | (12,067) | (12,036) | (11,764) | (11,748) | |||
| Other additional capital | 11,998 | |||||||
| Total stockholders' equity: | (72) | (31) | (22) | (6) | ||||
Income statement (P&L) ($ in thousands)
| 1/31/2022 Q1 | 10/31/2021 Q4 | 7/31/2021 Q3 | 4/30/2021 Q2 | 1/31/2021 Q1 | 10/31/2020 Q4 | ||
|---|---|---|---|---|---|---|---|
| Gross profit: | (6) | ||||||
| Operating expenses | (41) | (31) | (272) | (16) | (6) | ||
| Other undisclosed operating income | 6 | ||||||
| Operating loss: | (41) | (31) | (272) | (16) | (6) | ||
| Net loss attributable to parent: | (41) | (31) | (272) | (16) | (6) | ||
| Other undisclosed net income available to common stockholders, basic | 81 | 63 | |||||
| Net income (loss) available to common stockholders, diluted: | 41 | 31 | (272) | (16) | (6) | ||
Comprehensive Income ($ in thousands)
| 1/31/2022 Q1 | 10/31/2021 Q4 | 7/31/2021 Q3 | 4/30/2021 Q2 | 1/31/2021 Q1 | 10/31/2020 Q4 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (41) | (31) | (272) | (16) | (6) | ||
| Comprehensive loss, net of tax, attributable to parent: | (41) | (31) | (272) | (16) | (6) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.